In the fight against COVID-19, ImmunoScape is joining forces with Dr. Patrick Reeves, Team Leader at the Massachusetts General Hospital Vaccine & Immunotherapy Center, using its signature assay, TargetScape, to perform high-dimensional immune profiling of COVID-19 induced changes across immune populations and phenotypes with a focus on antigen-specific T cells. The study will investigate the […]
As part of a collective effort in fighting COVID-19, ImmunoScape is collaborating with Arcturus Therapeutics, a developer of RNA therapeutics for treatment and prevention of diseases with high unmet medical needs, and Duke-NUS, who will be running the clinical trial in healthy subjects in Singapore. The Arcturus LUNAR-COV19 vaccine, which uses Arcturus proprietary STARR™ and LUNAR® technologies is […]
ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology with $11M in Global Financing Led by Anzu Partners and UTEC
The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines
ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology Using T-Cell Immune Response Profiling Platform
ImmunoScape studying immune response to Covid-19
The Straits Times recently interviewed ImmunoScape executives to learn about their current global collaborations to help understand the immune response to Covid-19 and how they can aid vaccine development.